Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.46 |
| ▸ | FEN1 | P39748 | 4/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6587914 | 0.96 | CHEK2 (0.43) | ALOX5APFEN1CHEK2USP30PIK3CD | |
| SCHEMBL957928 | 0.90 | NOS3 (0.47) | ALOX5APFEN1CHEK2USP30PIK3CD | |
| SCHEMBL4291063 | 0.85 | PIK3CD (0.46) | CHEK2USP30PIK3CDGPR119NOS3 | |
| SCHEMBL6584944 | 0.84 | NOS3 (0.43) | PIK3CDHRH3NOS3NOS1NOS2 | |
| SCHEMBL15122119 | 0.82 | NOS3 (0.51) | ALOX5APFEN1CHEK2USP30PIK3CD | |
| SCHEMBL6695725 | 0.78 | CACNB4 (0.43) | CHEK2USP30NOS3NOS1NOS2 | |
| SCHEMBL28059314 | 0.77 | USP30 (0.56) | CHEK2USP30PIK3CDGPR119KDM1A | |
| SCHEMBL8248136 | 0.77 | USP30 (0.56) | CHEK2USP30PIK3CDGPR119KDM1A | |
| SCHEMBL1032633 | 0.77 | USP30 (0.56) | CHEK2USP30PIK3CDGPR119KDM1A | |
| SCHEMBL956395 | 0.76 | NOS3 (0.60) | CHEK2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0958282-B1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PROD INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
| EP-0958282-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | Pfizer Products Inc. (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998034919-A1 | 2-AMINO-6-(2-SUBSTITUTED-4-PHENOXY)-SUBSTITUTED-PYRIDINES | PFIZER PRODUCTS INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | ALOX5AP 251/4885FEN1 3816/4885CHEK2 3100/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | ALOX5AP 1604/4885FEN1 4809/4885CHEK2 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.